SSSeonghwan Seo

Seonghwan Seo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Seonghwan Seo has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Synthesis-aware generative design in trillion-scale chemical spaces for automated drug discovery

    by Seonghwan Seo, Yulseung Sung, Sang-Yeon Hwang, Mincheol Kang, Joonseong Lee, Samuele Bordi, Luka Raguž, Jihye Choi, Daniil Melnichenko, Wan Namkung, et al.

    Autonomous drug discovery via generative molecular design is critically bottlenecked by the production of chemically intractable structures. Multi-trillion-scale make-on-demand libraries guarantee synthetic feasibility, but conventional virtual screening cannot efficiently navigate these vast spaces or address multi-parameter optimization. We introduce Hyper Screening X, a generative AI framework integrating structure-based design with automated synthesis hardware. By encoding deterministic reaction logic in a generative flow network, the framework evaluates only 10 million candidates to navigate an 11-trillion-compound space, jointly optimizing physicochemical properties while ensuring compatibility with automated synthesis. Prospective validation against an SLC1A5 variant with a cryptic interface yielded a 96% synthesis success rate and a 50% functional hit rate, identifying two first-in-class lead compounds. This synthesis-aware strategy advances autonomous, closed-loop drug discovery.

  • Open Access

    AtlasFold: Protein structure prediction with metagenomic-scale language models

    by Seonghwan Seo, Hyeongwoo Kim, Seokhyun Moon, Woo Youn Kim, Team Kaist

    Protein language models (PLMs) trained on evolutionary sequences learn representations that encode protein structure, enabling direct structure prediction without multiple-sequence alignments (MSAs). Here we present the Atlas model family, an open and trainable system spanning protein language modeling, monomer folding, and protein-complex prediction. AtlasLM-3B is a 3B-scale language model trained with masked language modeling on approximately 1.56 billion sequences, including metagenomic data, and outperforms the similarly sized ESM2-3B in unsupervised contact prediction. Building on these representations, AtlasFold predicts all-atom protein structures and achieves state-of-the-art accuracy among PLM-based folding models. Fine-tuning AtlasFold for protein-complex prediction produces AtlasFold-Multimer (AtlasFold-M), whose antibody–antigen prediction performance is comparable to that of AlphaFold3 and ESMFold2. This protein-specific folding architecture enables fast, memory-efficient inference with AtlasFold and AtlasFold-M. By releasing the training code and data, stage checkpoints, and model weights under the MIT License, we provide a foundation for advancing PLM-based protein structure prediction. 1

  • Open Access

    PharmacoNet: deep learning-guided pharmacophore modeling for ultra-large-scale virtual screening

    by Seonghwan Seo, Woo Youn Kim

    PharmacoNet is developed for virtual screening, including deep learning-guided protein-based pharmacophore modeling, a parameterized analytical scoring function, and coarse-grained pose alignment. It is extremely fast yet reasonably accurate.


  • Open Access

    Molecular Generative Model via Retrosynthetically Prepared Chemical Building Block Assembly

    by Seonghwan Seo, Jaechang Lim, Woo Youn Kim

    Deep generative models are attracting attention as a smart molecular design strategy. However, previous models often render molecules with low synthesizability, hindering their real‐world applications. Here, a novel graph‐based conditional generative model which makes molecules by tailoring retrosynthetically prepared chemical building blocks until achieving target properties in an auto‐regressive fashion is proposed. This strategy improves the synthesizability and property control of the resulting molecules and also helps learn how to select appropriate building blocks and bind them together to achieve target properties. By applying a negative sampling method to the selection process of building blocks, this model overcame a critical limitation of previous fragment‐based models, which can only use molecules from the training set during generation. As a result, the model works equally well with unseen building blocks without sacrificing computational efficiency. It is demonstrated that the model can generate potential inhibitors with high docking scores against the 3CL protease of SARS‐COV‐2.


  • Open Access

    Drug-likeness scoring based on unsupervised learning

    by Kyunghoon Lee, Jinho Jang, Seonghwan Seo, Jaechang Lim, Woo Youn Kim

    A new quantification method of drug-likeness based on unsupervised learning. The method only uses drug molecules as training set without any non-drug-like molecules.